Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2009. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically detailing share allocations to Non-Executive Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to reporting director share allocations and does not contain financial performance data.
Material Changes
On December 31, 2008, Non-Executive Directors were provisionally allocated awards over Ordinary shares and American Depository Shares (ADSs) for the service period of October 1, 2008, to December 31, 2008. The allocation price was set at £12.58 per Ordinary share and $36.51 per ADS. These allocations were communicated to the Company and Directors on January 5, 2009.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly addresses compliance with Disclosure and Transparency Rule 3.1.4R(1)(a) regarding director transactions.
Key Facts for Investor Verification
- Allocation price for Non-Executive Director awards: £12.58 per Ordinary share and $36.51 per ADS.
- Service period covered by allocations: October 1, 2008, to December 31, 2008.
- Notification date of allocations: January 5, 2009.
- Specific share counts allocated to individual Non-Executive Directors (e.g., Sir Christopher Gent: 2,682.83 Ordinary Shares).
- Confirmation that this filing does not include financial results or operational guidance.